L-苏糖酸镁增强恩替卡韦对HBV感染小鼠的抗病毒作用及其机制

doi:10.13481/j.1671-587x.20200209

吉林大学学报(医学版) ›› 2020, Vol. 46 ›› Issue (02): 260-265.doi: 10.13481/j.1671-587x.20200209

L-苏糖酸镁增强恩替卡韦对HBV感染小鼠的抗病毒作用及其机制

钟哲峰¹, 谢靖婧¹, 何剑¹, 江波¹, 吕剑²

1. 南华大学附属南华医院感染科, 湖南衡阳 421002;
2. 南华大学附属南华医院儿科, 湖南衡阳 421002

收稿日期:2019-05-27 发布日期:2020-04-07
通讯作者: 吕剑,副主任医师(Tel:0734-6387876,E-mail:nanhua415@126.com) E-mail:nanhua415@126.com
作者简介:钟哲峰(1977-),男,湖南省湘乡市人,副主任医师,医学硕士,主要从事感染科疾病诊治方面的研究。
基金资助:
湖南省教育厅科研基金资助课题（17B231）；湖南省衡阳市科技局科学技术发展项目资助课题（2016KS12）

Enhancement effect of magnesium-L-threonate for antiviral effect of entecavir in HBV-infected mice and its mechanism

ZHONG Zhefeng¹, XIE Jingjing¹, HE Jian¹, JIANG Bo¹, LYU Jian²

1. Department of Infectious Diseases, Affiliated Nanhua Hospital, University of South China, Hengyang 421002, China;
2. Department of Pediatrics, Affiliated Nanhua Hospital, University of South China, Hengyang 421002, China

Received:2019-05-27 Published:2020-04-07

摘要/Abstract

摘要： 目的：观察L-苏糖酸镁（MLT）是否可增强恩替卡韦（ETV）对乙型肝炎病毒（HBV）感染小鼠的抗病毒作用，并初步探讨其机制。方法：采用高压水动力法经尾静脉注射携带1.3拷贝HBV基因组（ayw亚型）的重组8型腺相关病毒建立HBV持续感染的C57BL/6小鼠模型。成模后分为模型组、MLT组（1.2 g·kg^-1 L-苏糖酸镁胶囊）、ETV组（75 μg·kg^-1恩替卡韦片）、联合处理组（1.2 g·kg^-1 L-苏糖酸镁胶囊+75 μg·kg^-1恩替卡韦片），每组8只；另选取8只未经病毒感染的正常小鼠作为对照组，连续给药4周。采用ELISA法检测小鼠血清HBsAg和HBeAg水平；采用荧光定量PCR法检测小鼠肝脏组织及血清中HBV DNA拷贝数；分离小鼠外周血CD8+T细胞，检测小鼠血清及CD8+T细胞中Mg²⁺含量，并采用流式细胞仪检测小鼠外周血CD8+T细胞中表面分子程序性死亡受体1（PD-1）、自然杀伤细胞活化受体（NKG2D）、CD95和CD38表达水平。结果：与对照组比较，模型组小鼠血清和CD8+T细胞中Mg²⁺含量及CD8+T细胞中表面活化性分子NKG2D和CD38表达水平明显降低（P<0.05），而抑制性分子PD-1和CD95表达水平明显升高（P<0.05）；与模型组比较，各给药组小鼠血清HBsAg、HBeAg水平及肝脏组织和血清中HBV DNA拷贝数均明显降低（P<0.05），且联合处理组小鼠各指标改善效果最好；与模型组比较，MLT组和联合处理组小鼠血清及CD8+T细胞中Mg²⁺含量及CD8+T细胞表面活化性分子NKG2D和CD38表达水平明显升高（P<0.05），而抑制性分子PD-1和CD95表达水平明显降低（P<0.05），但ETV组小鼠各指标差异无统计学意义（P>0.05）。结论：MLT可增强ETV对HBV感染小鼠的抗病毒作用，其机制可能是MLT可引起CD8+T细胞内Mg²⁺含量增加，提高CD8+T细胞活性，进而更加有效地清除HBV。

关键词: 乙型肝炎病毒, L-苏糖酸镁, 恩替卡韦, CD8+T细胞

Abstract: Objective: To observe whether magnesium-L-threonate (MLT) can enhance the antiviral effect of entecavir (ETV) in the HBV-infected mice, and to explore its mechanism. Methods: The recombinant adeno-associated virus 8 carrying 1.3 copies of HBV genome was injected into the C57BL/6 mice by tail vein to establish the HBV persistent infection mouse models. After successful modeling, the mice were divided into model group, MLT group (1.2 g·kg^-1 magnesium-L-threonate capsules), ETV group (75 μg·kg^-1 entecavir tablets), and combined treatment group (1.2 g·kg^-1 magnesium-L-threonate caspules+75 μg·kg^-1 entecavir tablets) (n=8), and another 8 normal mice uninfected with HBV were selected as control group. Then all the mice were intragastrically administered for 4 weeks. The serum levels of HBsAg and HBeAg were detected by ELISA method, the copied of HBV DNA in liver tissue and serum of the mice were detected by quantitative real-time PCR. The peripheral blood CD8+ T cells were isolated, and the contents of Mg²⁺ in serum and CD8+ T cells were detected. The expression levels of PD-1, NKG2D, CD95 and CD38 in the CD8+ T cells were detected by flow cytometry. Results: Compared with control group, the contents of Mg²⁺ in serum and CD8+ T cells and the expression levels of surface activation molecules NKG2D and CD38 in the CD8+ T cells in model group were significantly decreased (P<0.05), while the expression levels of surface inhibitory molecules PD-1 and CD95 in the CD8+ T cells were significantly increased (P<0.05). Compared with model group, the expression levels of serum HBsAg and HBeAg, and the copied of HBV DNA in liver tissue and serum of the mice in various administration groups were significantly decreased (P<0.05), and the improvement degree of the indexes in combined treatment group was superior to other administration groups. Compared with model group, the contents of Mg²⁺ and the expression levels of NKG2D and CD38 in MLT group and combined treatment group were significantly increased (P<0.05), the expression levels of PD-1 and CD95 were significantly decreased (P<0.05), but there were no significant differences in ETV group (P>0.05). Conclusion: MLT can enhance the antiviral effect of ETV in the HBV-infected mice, and the mechanism may be that MLT can cause the increase of Mg²⁺ contents in the CD8+ T cells to improve the activity of CD8+ T cells, and thereby HBV can be removed more effectively.

Key words: hepatitis B virus, magnesium-L-threonate, entecavir, CD8+ T cells

中图分类号:

R512.62

钟哲峰, 谢靖婧, 何剑, 江波, 吕剑. L-苏糖酸镁增强恩替卡韦对HBV感染小鼠的抗病毒作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(02): 260-265.

ZHONG Zhefeng, XIE Jingjing, HE Jian, JIANG Bo, LYU Jian. Enhancement effect of magnesium-L-threonate for antiviral effect of entecavir in HBV-infected mice and its mechanism[J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 260-265.

参考文献

[1] GBD MORTALITY AND CAUSES OF DEATH COLLABORATORS. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet,2015,385(9963):117-171.
[2] GOLDSTEIN S T,ZHOU F J,HADLER S C,et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact[J]. Int J Epidemiol,2005,34(6):1329-1339.
[3] 郑文灿,余梅,法艳梅. 恩替卡韦在慢性乙型肝炎治疗中的应用进展[J]. 临床合理用药杂志,2018,11(13):177-179.
[4] MAINI M K,GEHRING A J. The role of innate immunity in the immunopathology and treatment of HBV infection[J]. J Hepatol,2016,64(1 Suppl):S60-S70.
[5] GEHRING A J,PROTZER U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology,2019,156(2):325-337.
[6] 刘畅,王红艳. CD8⁺ T细胞活化与分化的分子机制[J]. 中国免疫学杂志,2017,33(4):481-487.
[7] FERRARI C,BONI C,ROSSI M,et al. T cell regulation in HBV-related chronic liver disease[J]. J Hepatol,2017,66(5):1096-1098.
[8] 孙建军,冯辉. CD8⁺T细胞耗竭及靶向CD8⁺ T细胞免疫治疗的研究进展[J]. 免疫学杂志,2016,32(9):816-820.
[9] CHAIGNE-DELALANDE B,LI F Y,O'CONNOR G M,et al. Mg²⁺ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D[J]. Science,2013,341(6142):186-191.
[10] HUANG L R,WU H L,CHEN P J,et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection[J]. Proc Natl Acad Sci U S A,2006,103(47):17862-17867.
[11] 董小岩,尉迟捷,王刚,等. 高嗜肝性8型重组腺相关病毒体内转导法制备乙型肝炎病毒持续感染小鼠模型[J]. 病毒学报,2010,26(6):425-431.
[12] 石瑶,刘凤君,周仲辉,等. 恩替卡韦联合泼尼松对乙型肝炎病毒复制型小鼠体内病毒复制表达的影响[J]. 中华传染病杂志,2016,34(2):115-116.
[13] 黄飞,胡勤明,贺新祥. 恩替卡韦抗乙型肝炎病毒应答不佳患者挽救方案的疗效比较[J]. 肝脏,2018,23(8):721-723.
[14] PREDA C M,BAICUS C,NEGREANU L,et al. Effectiveness of entecavir treatment and predictive factors for virologic response[J]. Rev Esp Enferm Dig,2014,106(5):305-311.
[15] 隋洪华,徐永红,刘涵云,等. 恩替卡韦治疗慢性乙型肝炎过程中应答不佳相关因素分析[J]. 胃肠病学和肝病学杂志,2014,23(3):323-328.
[16] LI F Y,CHAIGNE-DELALANDE B,KANELLOPOULOU C,et al. Second messenger role for Mg²⁺ revealed by human T-cell immunodeficiency[J]. Nature,2011,475(7357):471-476.
[17] 邵红玲,彭丽,彭晓明. 慢性HBV感染者外周血CD8+T细胞中Mg²⁺水平及其临床意义[J]. 内科,2017,12(6):731-734.
[18] 唐宗生,郝友华,杨东亮.HBV持续性感染中T细胞功能耗竭的机制研究进展[J]. 中华肝脏病杂志,2012,20(11):871-873.
[19] 杨洋,冷静,彭丽珊,等. 慢性HBV感染者CD8+ T细胞CD95、CD38、HLA-DR表达的变化和意义[J]. 广东医学,2016,37(20):3043-3045.
[20] IM S J,HASHIMOTO M,GERNER M Y,et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy[J]. Nature, 2016, 537(7620):417-421.
[21] BENGSCH B,MARTIN B,THIMME R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J]. J Hepatol,2014,61(6):1212-1219.

L-苏糖酸镁增强恩替卡韦对HBV感染小鼠的抗病毒作用及其机制

Enhancement effect of magnesium-L-threonate for antiviral effect of entecavir in HBV-infected mice and its mechanism

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

Metrics

本文评价

推荐阅读 0

[1]	高鹏, 雒艳萍, 李俊峰. 乙型肝炎病毒对不同ALT状态下慢性乙型肝炎患者T淋巴细胞及其亚群的影响[J]. 吉林大学学报(医学版), 2020, 46(02): 359-364.
[2]	赵阳, 李烨, 齐玲, 赵臣. 替诺福韦酯和恩替卡韦治疗老年慢性乙型肝炎患者的抗病毒疗效及对致炎细胞因子的调节作用[J]. 吉林大学学报(医学版), 2019, 45(01): 117-122.
[3]	雷晓燕, 孙永红, 陈星星, 高霞, 宋元春, 赛依帕, 刘璟, 袁宏. 乙型肝炎病毒相关性肾小球肾炎患儿血清中HBV-cccDNA水平检测及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(06): 1256-1262.
[4]	于里涵, 谢峰, 郑涛, 付军, 阎龙, 杨甲梅. 血清前白蛋白在肝细胞癌患者肝切除术后复发风险评估中的应用[J]. 吉林大学学报(医学版), 2015, 41(03): 631-635.
[5]	白靓, 成岩, 徐芳菲, 刘燕, 张树军, 曹瑞珍. 金黄色葡萄球菌IsdB表位蛋白与HBc蛋白融合表达[J]. 吉林大学学报(医学版), 2015, 41(02): 269-274.
[6]	马莉\|张蔚\|许刚柱\|姚杨\|徐利\|刘凯歌. 乙型肝炎病毒相关性肝癌患者癌组织中HBx和CEACAM1的表达及其意义[J]. J4, 2012, 38(4): 779-783.
[7]	华瑞，华芳，陈海英，王峰，牛俊奇. 电穿孔法增强HBV DNA疫苗免疫效果的评价[J]. J4, 2008, 34(2): 347-350.
[8]	汪杨，牛俊奇，王峰. RNA干涉对乙型肝炎病毒复制和表达的影响[J]. J4, 2007, 33(4): 616-620.
[9]	张凯宇，牛俊奇，王玥，丁艳华，李玉香，王峰. 乙型肝炎病毒前-C区1896和基本C区启动子区1762、1764双突变及YMDD变异对拉米呋啶治疗的影响[J]. J4, 2005, 31(2): 176-178.